We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-9.41%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$982M
AUM Growth
+$21.4M
Cap. Flow
+$184M
Cap. Flow %
18.72%
Top 10 Hldgs %
37.6%
Holding
143
New
43
Increased
40
Reduced
5
Closed
15

Top Buys

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$29.1M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$19.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$15.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$15.4M
5
TDOC icon
Teladoc Health
TDOC
+$12.2M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$24.5M
2
MOR
MorphoSys AG American Depositary Shares
MOR
+$14.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.44M
4
NTLA icon
Intellia Therapeutics
NTLA
+$5.5M
5
BLUE
bluebird bio
BLUE
+$3.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.92%
2 Technology 1.53%
3 Real Estate 0.71%
4 Communication Services 0.66%
5 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARS icon
1
Tarsus Pharmaceuticals
TARS
$2.56B
$61.3M 6.24%
2,254,797
– –
EOLS icon
2
Evolus
EOLS
$394M
$52.6M 5.36%
4,847,399
+700,000
+17% +$8.61M
KALV
3
DELISTED
KalVista Pharmaceuticals
KALV
$49.7M 5.06%
4,218,829
+93,484
+2% +$1.09M
MIRM icon
4
Mirum Pharmaceuticals
MIRM
$6.89B
$44M 4.48%
1,287,107
+100,000
+8% +$2.62M
ANAB icon
5
AnaptysBio
ANAB
$1.6B
$33.4M 3.4%
1,330,879
– –
ANIP icon
6
ANI Pharmaceuticals
ANIP
$1.77B
$28.7M 2.92%
450,000
+300,000
+200% +$19.5M
DVAX
7
DELISTED
Dynavax Technologies
DVAX
$28.1M 2.86%
+2,500,000
New +$29.1M
LLY icon
8
Eli Lilly
LLY
$1.07T
$24.4M 2.49%
27,000
– –
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$4.25B
$24.4M 2.48%
1,500,000
+981,100
+189% +$15.8M
PCVX icon
10
Vaxcyte
PCVX
$7.89B
$22.7M 2.31%
300,000
– –
PTCT icon
11
PTC Therapeutics
PTCT
$6.37B
$21.4M 2.18%
700,000
– –
ITCI
12
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$20.5M 2.09%
300,000
+150,000
+100% +$10.4M
ALT icon
13
Altimmune
ALT
$539M
$18.3M 1.86%
2,750,000
– –
VRDN icon
14
Viridian Therapeutics
VRDN
$2.13B
$18.1M 1.85%
1,392,925
+700,000
+101% +$9.69M
AVDL
15
DELISTED
Avadel Pharmaceuticals
AVDL
$17.3M 1.76%
1,230,000
+182,725
+17% +$2.98M
CRSP icon
16
CRISPR Therapeutics
CRSP
$4.58B
$17.1M 1.74%
316,500
+200,000
+172% +$11.6M
RCKT icon
17
Rocket Pharmaceuticals
RCKT
$348M
$16.1M 1.64%
750,000
+90,000
+14% +$2.07M
CGEM icon
18
Cullinan Oncology
CGEM
$1.05B
$16.1M 1.64%
921,138
+350,000
+61% +$7.45M
AUPH icon
19
Aurinia Pharmaceuticals
AUPH
$1.97B
$15.9M 1.62%
2,779,500
+729,500
+36% +$3.84M
GSK icon
20
GSK
GSK
$103B
$15.4M 1.57%
400,000
+100,000
+33% +$4.21M
JAZZ icon
21
Jazz Pharmaceuticals
JAZZ
$15.9B
$14.9M 1.52%
+140,000
New +$15.4M
AVIR icon
22
Atea Pharmaceuticals
AVIR
$379M
$14.8M 1.51%
4,476,741
+400,000
+10% +$1.49M
NVDA icon
23
NVIDIA
NVDA
$5.01T
$14.2M 1.45%
115,019
+15,019
+15% +$1.52M
IMCR icon
24
Immunocore
IMCR
$1.78B
$13.7M 1.4%
405,600
– –
LENZ
25
LENZ Therapeutics
LENZ
$172M
$12.9M 1.32%
747,616
+200,000
+37% +$3.49M
1
2 3 4 5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $1.98B AUM 1.62% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return

Tang Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Tang Capital Management held 143 positions worth $982M, up 2.2% from $960M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tang Capital Management deployed $184M of net new capital in Q2 2024, opening 43 new positions and adding to 40 existing holdings. Its largest new stake was Dynavax Technologies: 2,500,000 shares worth $28.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Technology and Real Estate.

On the sell side, the largest reduction was Quince Therapeutics, an estimated $1.31M trimmed.

  • Tang Capital Management's largest Q2 2024 buy was Dynavax Technologies: 2,500,000 shares worth $28.1M.
  • Tang Capital Management added most to ANI Pharmaceuticals in Q2 2024, an estimated $19.5M increase.
  • Tang Capital Management's biggest Q2 2024 reduction was Quince Therapeutics, cutting an estimated $1.31M.
  • Tang Capital Management fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $24.5M.
  • Tang Capital Management's ten largest holdings make up 38% of its $982M portfolio in Q2 2024.
  • Tang Capital Management opened 43 new positions and closed 15 in Q2 2024.
  • Tang Capital Management's portfolio value rose 2.2% quarter-over-quarter to $982M.

Based on Tang Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.